ArticleNature2023
Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution.
Abstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 552 papers.
0numbers the graph read from it
0cells of the map it votes in
552citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
552 citing papers in PubMed.
- Safety, tolerability, and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody SA55 injection in healthy participants.Antimicrobial agents and chemotherapy · 2025Trial
- Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Deep mutational scanning reveals the antibody escape and infectivity landscape of SARS-CoV-2 Omicron JN.1 and XEC receptor-binding domains.Emerging microbes & infections · 2026Article
- Safety, Pharmacokinetics, and Predicted Neutralizing Activity of the SARS-CoV-2 Monoclonal Antibody Sipavibart: Results from Little DIPPER and the SUPERNOVA Substudy.Infectious diseases and therapy · 2026Article
- Gapmers targeting conserved SARS-CoV-2 single-stranded regions reduce viral load and reshape inflammatory macrophage responses.iScience · 2026Article
- An inverse-protein-folding pre-trained model for predicting the mutational effects in protein-protein interactions.iScience · 2026Article
- Design of Epitope-Focused Vaccines via Epitope Cleavage.ACS central science · 2026Article
- Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses.Journal of virology · 2026Article
- Transmission of mutated SARS-CoV-2 variants is favored by relatively prolonged infections due to delayed immunity.bioRxiv : the preprint server for biology · 2026Article
- Article
- R1-32-like public antibodies acquire tolerance to SARS-CoV-2 antigenic drift through somatic hypermutation.PLoS biology · 2026Article
- Development of a potential vaccine against dengue and chikungunya virus co-infection using immunoinformatics and structural evaluation.Journal, genetic engineering & biotechnology · 2026Article
- Serum Escape Landscape of SARS-CoV-2 Omicron JN.1 and XEC RBD Under COVID-19 Vaccine Breakthrough Immunity in China.Microorganisms · 2026Article
- A blinded, prospective benchmark of in silico antibody discovery anchored to experimental affinity and developability.Nature biotechnology · 2026Article
- Structural and Mechanistic Perspectives on SARS-CoV-2 Nonstructural Protein 14-Mediated Cap Formation and Drug Discovery.Microorganisms · 2026Review
- A computational method to design broad-spectrum T cell-inducing vaccines applied to Betacoronaviruses.Cell reports methods · 2026Article
- Immune evasion, infectivity, and membrane fusion of SARS-CoV-2 variants LP.8.1.1, XEC.25.1, XFG, and NB.1.8.1.Microbiology spectrum · 2026Article
- Tracking the shifting landscape of SARS-CoV-2 variants in Lebanon among healthcare workers and hospitalized patients.Microbiology spectrum · 2026Article
- Counteracting Influenza Virus Evolution Through the Full Spectrum of Broadly Protective Antibodies.Immunological reviews · 2026Review
- Receptor-mimicking antibodies retain neutralization of recent SARS-CoV-2 variants.Biosafety and health · 2026Article
492 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Yunlong Cao *Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China. yunlongcao@pku.edu.cn.ORCID 0000-0001-5918-1078
Fanchong Jian *Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.ORCID 0000-0001-8703-3507
Jing Wang *Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.ORCID 0000-0002-9084-9985
Yuanling Yu *Changping Laboratory, Beijing, P. R. China.
Weiliang Song *Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
Ayijiang YisimayiBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
Jing WangChangping Laboratory, Beijing, P. R. China.
Ran AnChangping Laboratory, Beijing, P. R. China.
Xiaosu ChenInstitute for Immunology, College of Life Sciences, Nankai University, Tianjin, P. R. China.
Na ZhangChangping Laboratory, Beijing, P. R. China.
Yao WangChangping Laboratory, Beijing, P. R. China.
Peng WangChangping Laboratory, Beijing, P. R. China.
Lijuan ZhaoChangping Laboratory, Beijing, P. R. China.
Haiyan SunChangping Laboratory, Beijing, P. R. China.
Lingling YuChangping Laboratory, Beijing, P. R. China.
Sijie YangBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
Xiao NiuBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
Tianhe XiaoBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
Qingqing GuChangping Laboratory, Beijing, P. R. China.ORCID 0000-0001-5805-6419
Fei ShaoChangping Laboratory, Beijing, P. R. China.
Xiaohua HaoBeijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.
Yanli XuBeijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.
Ronghua JinBeijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.ORCID 0000-0001-8496-172X
Zhongyang ShenOrgan Transplant Center, NHC Key Laboratory for Critical Care Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, P. R. China.ORCID 0000-0003-0045-4355
Youchun WangChangping Laboratory, Beijing, P. R. China. wangyc@nifdc.org.cn.ORCID 0000-0001-9769-5141
Xiaoliang Sunney XieBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China. sunneyxie@biopic.pku.edu.cn.ORCID 0000-0001-9281-5239
Funding
No grant is acknowledged in the PubMed record.
Abstract
Continuous evolution of Omicron has led to a rapid and simultaneous emergence of numerous variants that display growth advantages over BA.5 (ref.
Indexed as
Antibodies, ViralAntigenic Drift and ShiftCOVID-19Evolution, MolecularImmunity, HumoralSARS-CoV-2Spike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2Antibodies, MonoclonalAntibodies, NeutralizingBreakthrough InfectionsCOVID-19 SerotherapyCOVID-19 VaccinesHumansImmunization, SecondaryMutationACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.